Eikon Therapeutics, Inc. balance sheet EIKN

As of Jun 30, 2026, Eikon Therapeutics, Inc. had total assets of $779.6 million and total liabilities of $313.1 million. Stockholders' equity was $466.5 million. It held $531.2 million in cash and investments against $252.2 million of total debt, net cash of $279.0 million. The current ratio, current assets divided by current liabilities, was 9.89.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
143
161
Short-term investments
389
351
Long-term investments
—
84
Cash and investments
531
596
Total current assets
547
530
Property and equipment, net
133
138
Total assets
780
851
Liabilities and equity
Accounts payable
7
6
Total current liabilities
55
45
Total liabilities
313
300
Stockholders' equity
466
551
Debt
Lease liabilities
252
255
Total debt
252
255
Net cash
279
341
Ratios
Current ratio
9.89x
11.75x
Debt to equity
0.54x
0.46x
Book value per share
8.62
10.17
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
EIKN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Millbrae, CA
SEC filer status
, Emerging growth company
SEC CIK
1861123

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.